Floatz logo

TACROLIMUS

Lymphoproliferative Disorder

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Lymphoproliferative Disorder cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Baclofen
Alliance for Clinical Trials in Oncology
Phase 3BB
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB

View all 50 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →